Compare Novo Nordisk A/S (NVO) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Atlassian Corporation PLC — how do they compare? Novo Nordisk A/S trades at $49.31 (market cap $220.53B), while Atlassian Corporation PLC trades at $90.53 (market cap $23.67B). The key difference: Novo Nordisk A/S is far larger — about 9.3× Atlassian Corporation PLC's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| NVO | TEAM | |
|---|---|---|
Market Cap | $220.53B | $23.67B |
Sector | Health | Technology |
52-Week High | $71.70 | $203.00 |
52-Week Low | $35.29 | $57.15 |
Enterprise Value | $239.49B | $23.78B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Atlassian (TEAM) trades at $90.60, down 2.88% on the day, with a bullish technical signal from moving averages and strong analyst support (67% buy ratings). The company shows accelerating revenue growth, reaching $5.22B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven product enhancements and enterprise adoption momentum, with the Service Collection surpassing $1B in annual recurring revenue.
TEAM presents a growth investment case with a consensus price target of $114.54 (26% upside), supported by cloud momentum and AI integration. However, persistent net losses (-$256.69M in 2025) and high valuation multiples (P/S 3.96, P/B 26.93) pose risks amid competitive pressures and macroeconomic sensitivity in software spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
